The Future Vision in Health Services Meeting, jointly organized by OHSAD (Association of Private Hospitals and Health Institutions) and TUSAP (Turkey Health Platform), was held on 14 September 2024 at Basaksehir Cam and Sakura City Hospital in Istanbul.
The meeting brought together senior health authorities, executives from public and private hospitals, representatives of university hospitals and many professionals from across the healthcare sector. The discussions focused on the future of health services, digital transformation and innovation, and provided an important platform for exchanging views on these key topics.
As World Medicine, we took part in this important event with our national investment, the WMINOLAB Innovation Laboratory, which was established to support Türkiye’s goal of a sustainable and independent future in pharmaceutical production. We had the opportunity to present our leading role in the pharmaceutical sector and the significant contribution we make to pharmaceutical analysis in Türkiye.
The Minister of Health, Prof. Dr. Kemal Memişoğlu, visited our booth and received detailed information from our Vice Chairman of the Board, Mr. Sohrab Mammadov, and our R&D and Regulatory Affairs Director, Mr. Erdinç Babuç, regarding WMINOLAB’s activities and our ongoing R&D investments.
Equipped with advanced mass spectrometry instruments such as LC-MS/MS, GC-MS, ICP-MS and LC-QTOF, our laboratory enables the performance of critical analyses, including structural elucidation of substances, elemental impurities, nitrosamine impurities and the control of impurities that may migrate from primary packaging materials into the product, all in line with international standards.
During the highly productive sessions and bilateral meetings, we emphasized that our laboratory is open to all institutions and organizations in need, and that our primary goals are to reduce external dependence in drug analysis, contribute to the national economy and support domestic pharmaceutical manufacturing. We reiterated our commitment to continuing our efforts to help Türkiye achieve a sustainable and independent future in pharmaceutical production.